UBS O'Connor’s Pliant Therapeutics PLRX Stock Holding History

UBS O'Connor’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-103,563	Closed	-$1.36M	–	430
2024 Q4	$1.36M	Buy	103,563 +18,678	+22%	+$255K	0.03%	205
2024 Q3	$952K	Buy	84,885 +7,885	+10%	+$98.7K	0.02%	283
2024 Q2	$828K	Buy	+77,000	New	+$993K	0.02%	320
2023 Q2	–	Sell	-10,500	Closed	-$279K	–	630
2023 Q1	$279K	Buy	+10,500	New	+$299K	0.01%	499

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

UBS O'Connor's PLRX Position: Q1 2025 in Review

UBS O'Connor sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 103,563 shares — an estimated $1.36M sold.

UBS O'Connor first reported a position in PLRX in Q1 2023 and held it in 4 quarters. The position peaked at $1.36M in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

UBS O'Connor reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
UBS O'Connor sold 103,563 Pliant Therapeutics shares in Q1 2025, an estimated $1.36M.
UBS O'Connor first reported a position in Pliant Therapeutics in Q1 2023 and held it in 4 quarters.
UBS O'Connor's Pliant Therapeutics position peaked at $1.36M in Q4 2024.
140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.